Cibus (CBUS) investor relations material

Company overview and business model

• Focuses on agricultural biotechnology, using proprietary gene editing to develop plant traits for major crops.

• Rapid Trait Development System™ enables integration of novel traits into elite seed genetics in as little as one year.

• Near-term pipeline prioritizes Rice herbicide tolerance traits and sustainable ingredients, including lauric oils and biofragrance products.

• Biofragrance business estimated to have $20–40 million peak annual revenue potential in a $75 billion global market by 2030.

• Operates as a holding company with all assets and operations through Cibus Global, LLC and subsidiaries.

Financial performance and metrics

• As of March 31, 2026, held $30.3 million in cash and cash equivalents and $13.9 million in current liabilities.

• Net tangible book deficit as of March 31, 2026, was $(228.3) million, or $(2.99) per share.

• Immediate dilution to new investors in the ATM offering estimated at $3.14 per share at an assumed $1.50 offering price.

• Approximately $570.8 million in federal and state net operating loss carryforwards as of December 31, 2025.

• Auditor’s report includes a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Proceeds from offerings intended for general corporate purposes, including R&D, working capital, debt repayment, and capital expenditures.

• ATM and warrant exercise proceeds may also fund further development of weed management traits in Rice and facilities-related costs.

• Management retains broad discretion over allocation and timing of expenditures.